New hope for rare bone cancer: targeted drug AG-120 tested in small trial

NCT ID NCT04278781

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tests whether the drug AG-120 can safely slow or stop the growth of a rare bone cancer called chondrosarcoma that has a specific IDH1 gene mutation. Six adults with advanced or recurrent grade 2 or 3 chondrosarcoma will receive the drug. The main goal is to see how long the cancer stays under control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHONDROSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chondrosarcoma follicular lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Columbia University (Specimen Analysis Only)

    New York, New York, 10032, United States

  • Johns Hopkins Hospital (Data Collection Only)

    Baltimore, Maryland, 21287, United States

  • MD Anderson Cancer Center (Data Collection Only)

    Houston, Texas, 77030, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • The Ohio State University (Data Collection Only)

    Columbus, Ohio, 43210, United States